Dhadhang Kurniawan, MSc

Position: PhD Student    
Education: MSc Pharmaceutical Sciences
In the Lab since: 2016
Main Research: Nano-therapeutics for the targeted modulation of inflammatory macrophages in liver diseases
Research Interests: - Nanomedicine
                                    - Inflammatory Macrophages
                                    - Liver Diseases  
My Personal Goal: Discovering and development novel therapeutics for the treatment of liver diseases

Contact: d.w.kurniawan@utwente.nl
Location: ZH 253

My research

Liver diseases is a growing health problem with a worldwide mortality of around 1.5 million death per year attributable to cirrhosis and hepatocellular carcinoma. Most of the liver diseases such as chronic hepatitis B, hepatitis C, alcoholic liver disease and non-alcoholic liver disease leads to fibrosis. Hepatocyte damage due to liver injury leads to the release of pro-fibrotic factors from infiltrated inflammatory cells, especially macrophages resulting in the activation of key pathogenic cells i.e. hepatic stellate cells. So, my PhD research now is focused on how to inhibit inflammatory macrophages using nanoparticles.

About me

I obtained my bachelor degree from School of Pharmacy Institut Teknologi Bandung, Indonesia. Since April 2006, I was a lecturer at Department of Pharmacy Universitas Jenderal Soedirman, Indonesia. During to be a lecturer, I also performed research related to pharmaceutical technology field, in line with the course which I teach. At 2011, I graduated from Master Program at Faculty of Pharmacy Universitas Gadjah Mada, Indonesia. My master thesis about the synthesis of thiolated chitosan as a matrix for the preparation of metformin hydrochloride microparticles.

Since 1 February 2016, I joined as a PhD student in Targeted Therapeutics Group, Department of Biomaterial and Science Technology University of Twente The Netherlands.


Kurniawan DW., Jajoriya AK., Dhawan G., Mishra D., Argemi J., Bataller R., Storm G., Mishra DP., Prakash J., Bansal R.
''Therapeutic inhibition of spleen tyrosine kinase in inflammatory macrophages using PLGA nanoparticles for the treatment of non-alcoholic steatohepatitis.''
J. Control. Release 2018 Oct 28;288:227-238. doi: 10.1016/j.jconrel.2018.09.004. Epub 2018 Sep 13.
PMID: 30219279